chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea
Clinical narrative: Diarrhea; This is a spontaneous report from a contactable consumer or other non Healthcare Professional (the patient, reported for self). A 74-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Batch/Lot Number: EN6205), via an unspecified route of administration, administered in Arm right on 15Mar2021 (at the age of 74-years-old) as dose 2, single for COVID-19 immunization. The patient had earlier received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Batch/Lot Number: EL9265), via an unspecified route of administration, administered in Arm right on 20Feb2021 05:30 PM, (at the time of vaccination 74-years-old), as dose 1, single for COVID-19 immunization. The patient medical history was not reported. The patient concomitant medications, list of any other medications the patient received within 2 weeks of vaccination included: Atorvastatin, Allopurinol, Metformin, plus others all for unspecified indication from unspecified dates. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 Prior to vaccination. On 20Mar2021 22:00, the patient experienced diarrhea, which has continued through this date - 23Mar2021 at 8:30p.m. Patient visited to Doctor or other healthcare professional office/clinic as a result of adverse event. The patient has not been tested for COVID-19 since the vaccination. Treatment received for the adverse events includes: Ingesting one tablespoon of castor oil 2x daily. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Vaccination site pain
Clinical narrative: Sore arm near the site of injection; Muscle aches; Fatigue; This is spontaneous report from a contactable consumer, the patient.  A 64-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the left arm on 16Mar2021 at 14:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. The patient did not have any allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 16Mar2021 at 18:00, the patient experienced sore arm near the site of injection, muscle aches and fatigue. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events sore arm near the site of injection, muscle aches and fatigue. The clinical outcomes of the events sore arm near the site of injection, muscle aches and fatigue were recovered on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, SARS-CoV-2 test
Clinical narrative: Swollen lymph nodes in armpit of arm that received vaccine; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727), via an unspecified route of administration in the left arm on 20Mar2021 at 12:00 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history included mitral valve prolapse with heart murmur. The patient did not take any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 21Mar2021 at 16:00, the patient experienced swollen lymph nodes in armpit of arm that received the vaccine. The patient underwent lab test and procedures which included PCR nasal swab in Sep2020 and tested negative. The patient did not receive any treatment for swollen lymph nodes. The event did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the event swollen lymph nodes was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Vomiting
Clinical narrative: Chills that lasted for over four hours; Diarrhea that is lasting over 12 hours; vomiting; This is a spontaneous report received from a non-contactable consumer, the patient. A 33-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 19Mar2021 (at the age of 33-year-old) as a single dose, for COVID-19 immunisation. Medical history included high blood pressure and obesity. The patient had a history of allergies to milk products. Concomitant medications included Lisinopril (MANUFACTURER UNKNOWN), water pill (MANUFACTURER UNKNOWN) (unspecified), vitamin d (MANUFACTURER UNKNOWN) and vitamin b12 (MANUFACTURER UNKNOWN), for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 21Mar2021 at 11:30, the patient experienced chills, diarrhoea and vomiting. Treatment was not received for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events chills (lasted for over four hours) and diarrhoea (lasted over 12 hours) was resolved on 21Mar2021 at 15:30 and 21:20 respectively, whereas event vomiting was resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Hypoaesthesia, Lip swelling, Palpitations
Clinical narrative: Dizziness; Heart palpitations; Mild numbness; Tingling of tongue; Mild lower lip swelling; Frequent urination; Fever of 99; Wrong site of drug administration; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9269) via an unspecified route on left leg (wrong site of drug administration) on 21Mar2021 at 13:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto thyroidism and celiac disease. The patient was allergic to wheat, dairy, nitrous oxide and codeine. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included B12 shot (MANUFACTURER UNKNOWN) for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested positive for COVID-19. On 21Mar2021 at 13:15, the patient experienced dizziness for about an hour, with heart palpitations, mild numbness, tingling of tongue, mild lower lip swelling, frequent urination (urinated 8 times in one hour) and fever of 99 (units unspecified). The events not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment received for the adverse events. The clinical outcome of the events dizziness, heart palpitations, mild numbness, tingling of tongue, mild lower lip swelling, frequent urination and fever of 99 were resolved on 21Mar2021. The clinical outcome of the event wrong site of drug administration was unknown. No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia oral, Pollakiuria, Product administered at inappropriate site, Pyrexia
Clinical narrative: Dizziness; Heart palpitations; Mild numbness; Tingling of tongue; Mild lower lip swelling; Frequent urination; Fever of 99; Wrong site of drug administration; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9269) via an unspecified route on left leg (wrong site of drug administration) on 21Mar2021 at 13:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto thyroidism and celiac disease. The patient was allergic to wheat, dairy, nitrous oxide and codeine. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included B12 shot (MANUFACTURER UNKNOWN) for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested positive for COVID-19. On 21Mar2021 at 13:15, the patient experienced dizziness for about an hour, with heart palpitations, mild numbness, tingling of tongue, mild lower lip swelling, frequent urination (urinated 8 times in one hour) and fever of 99 (units unspecified). The events not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment received for the adverse events. The clinical outcome of the events dizziness, heart palpitations, mild numbness, tingling of tongue, mild lower lip swelling, frequent urination and fever of 99 were resolved on 21Mar2021. The clinical outcome of the event wrong site of drug administration was unknown. No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Extreme tiredness  4 days out; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration, on 17Mar2021, at 12:00, (at the age of 60 years), on left arm, as a single dose for COVID-19 immunisation. Medical history included sulfas allergy, bactrim and other urinary tract infection antibiotics however the patient was ok with cephalex. Concomitant medications included VRAYLAR, NEURONTIN, aspirin (MANUFACTURER UNKNOWN), lovastatin (MANUFACTURER UNKNOWN), LUVOX started on unknown date for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021, at 1200 the patient experienced extreme tiredness and 4 days out. Therapeutic measure were not taken for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tiredness was not recovered at time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, Vaccination site vesicles
Clinical narrative: Water blister at injection site; Itchy rash covering entire upper arm; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route in the right arm on 12Mar2021 at 12:30 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma and complex region pain syndrome (CRPS). The patient was allergic to gluten, latex, band aid and tape. Concomitant medication was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took NEOSPORIN and experienced allergies to it. On 12Mar2021 at 16:00, the patient experienced water blister at injection site and itchy rash covering entire upper arm. The patient did not receive any treatment for the adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of water blister at injection site and itchy rash covering entire upper arm was not resolved at the time of this report.  Information about lot/batch number cannot be obtained. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Poor quality sleep, Vaccination site pain
Clinical narrative: Did not sleep well; feeling very tired; headache; soreness at the injectionsite; This is a spontaneous report from a non-contactable consumer. A 64-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot Number: unknown), via an unspecified route of administration in the left arm on 20Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot number: unknown), via an unspecified route of administration in the left arm on 27Feb2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. On 20Mar2021, the patient experienced feeling very tired, significant headache for most of the day and soreness at the injection site. The patient did not sleep well the previous night due to the headache. The patient did not receive any treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of feeling very tired, significant headache, did not sleep well and soreness at the injection site was resolved on an unspecified date in 2021.   Information about lot number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache
Clinical narrative: Dizziness; Fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER6213) via an unspecified route of administration in left arm on 17Mar2021 at 20.45 (at the age of 36-years-old) as a single dose , for COVID-19 immunisation. Medical history included celiac, asthma and penicillin allergy. Concomitant medication included XOPENEX for unknown indication and SYMBICORT for unknown indication. The patient did not receive other vaccines in four weeks.  It was unknown if the patient was diagnosed with COVID prior to vaccination and the patient was not tested for COVID  post vaccination. On 18Mar2021 the patient experienced dizziness, fatigue and headache.  The patient did not receive any treatment for the events. The clinical outcome of dizziness, fatigue and headache was not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dizziness, Feeling abnormal, Headache, Joint swelling
Clinical narrative: Joint Swelling; slightly light headedness; Brain fog; Slight headache; Joint Swelling and pain; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206) via an unspecified route of administration on 09Mar2021 at 13:30 (at the age of 75 years) on right arm as a single dose for COVID-19 immunisation. Medical history included arthritis. The patient was allergic to shellfish and some antibiotics and she was not allergic to any other vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9266) via an unspecified route of administration on 16Feb2021 at 13:30, on right arm as a single dose for COVID-19 immunisation. The patient did not receive any medication with in the 2 weeks of vaccination The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 09Mar2021, at 16:00, the patient slept for 12 hours and then she experienced slight headache, joint swelling and pain, brain fog, and slight light headed. It was reported that events continued even after 10 days after 2nd dose. No treatment received as a result of event. The clinical outcome of headache, joint swelling, joint pain and light headedness were not recovered.   No follow-up are attempts possible. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Neck pain
Clinical narrative: chest pain on the left side; neck pain also on the left side; This is a spontaneous report received from a contactable consumer, the patient. A 25 years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route on 19Mar2021 at 15:45, (at the age of 25-years-old) on the left arm as a single dose, for COVID-19 immunisation. The medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the vaccination. On 19Mar2021, at 16.30, after an hour of vaccination, the patient experienced slight chest pain and neck pain on the left side. No treatment was received by the patient for the reported events and the events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of chest pain on left side and neck pain on left side was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Lethargy, Limb discomfort, Pain in extremity
Clinical narrative: heaviness; lethargy; Soreness in arm; soreness in hips; This is a spontaneous report from contactable consumer, the patient. A 49-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 18Mar2021 at 19:15 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. The patient did not have any medical history and was allergic to penicillin. The concomitant medications included MULTIVITAMIN, VITAMIN C, OSTEO BI FLEX, calcium (MANUFACTURER UNKNOWN), VITAMIN E for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 06:00, the patient experienced soreness in arm, heaviness in arm, lethargy, soreness in hips. No therapeutic measures were taken for the reported events. The events had not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of soreness in arm, heaviness in arm, lethargy, soreness in hips was not resolved at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Myalgia, Nausea
Clinical narrative: Had sore throat; Nausea; Chills; Tiredness; Muscle pain; 101.2 fever; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 18Mar2021 at 12:00 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have allergies to medications, food, or other products. On 19Mar2021 at 12:00, the patient experienced sore throat, chills, tiredness, muscle pain, nausea and fever. On 19Mar2021, the body temperature was reported as 101.2 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events sore throat, chills, tiredness, muscle pain, nausea and fever were recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia
Clinical narrative: Had sore throat; Nausea; Chills; Tiredness; Muscle pain; 101.2 fever; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 18Mar2021 at 12:00 (at the age of 55-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have allergies to medications, food, or other products. On 19Mar2021 at 12:00, the patient experienced sore throat, chills, tiredness, muscle pain, nausea and fever. On 19Mar2021, the body temperature was reported as 101.2 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events sore throat, chills, tiredness, muscle pain, nausea and fever were recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Generalised numbness; This is a spontaneous report received from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN5318) via an unspecified route of administration in the right arm on 26Feb2021 at 12:00 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included vitamins. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 13Mar2021 at 12:00, about 15 days after the vaccine, the patient began to experience numbness in her leg which over the next day travelled to her right side, and eventually to her face and mouth. The sensation increased and decreased in intensity and location but never completely went away. The patient visited a doctor and they thought the vaccine triggered a reaction in her L5 band for which she was prescribed medication. Therapeutic treatment taken for the reported event was celecoxib, tizanidine and gabapentin. The patient underwent lab tests and procedures, which included blood test and an MRI on her head which showed nothing of interest to the doctors. The clinical outcome of the generalised numbness was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Malaise, Nausea, Pruritus
Clinical narrative: Pain and swelling at injection site; Pain and swelling at injection site; Nausea; dizziness; fatigue; feeling unwell; itchy skin; This is a spontaneous report received from a contactable nurse, the patient. A 35-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route in the left arm on 19Mar2021 at 09:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient was allergic to bee stings. No concomitant medications were reported. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 19Mar2021 at 11:45, the patient had pain and swelling at injection site, nausea, dizziness, fatigue, feeling unwell and itchy skin. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events pain and swelling at injection site, nausea, dizziness, fatigue, feeling unwell and itchy skin was unknown at the time of reporting.    No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling
Clinical narrative: Pain and swelling at injection site; Pain and swelling at injection site; Nausea; dizziness; fatigue; feeling unwell; itchy skin; This is a spontaneous report received from a contactable nurse, the patient. A 35-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route in the left arm on 19Mar2021 at 09:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient was allergic to bee stings. No concomitant medications were reported. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 19Mar2021 at 11:45, the patient had pain and swelling at injection site, nausea, dizziness, fatigue, feeling unwell and itchy skin. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events pain and swelling at injection site, nausea, dizziness, fatigue, feeling unwell and itchy skin was unknown at the time of reporting.    No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chest pain, Chills, Dry throat
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6213) via an unspecified route of administration in right arm on 18Mar2021 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, diabetes and allergic to ibuprofen. The patient received unspecified concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6198) via an unspecified route of administration in left arm on 25Feb2021 at 12.15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021 at 1600, the patient experienced injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat and dry sinuses. No treatment was received for the adverse events. The clinical outcome of injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat, dry sinuses was resolved on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Malaise, Pyrexia, Sinus disorder
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6213) via an unspecified route of administration in right arm on 18Mar2021 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, diabetes and allergic to ibuprofen. The patient received unspecified concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6198) via an unspecified route of administration in left arm on 25Feb2021 at 12.15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021 at 1600, the patient experienced injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat and dry sinuses. No treatment was received for the adverse events. The clinical outcome of injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat, dry sinuses was resolved on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6213) via an unspecified route of administration in right arm on 18Mar2021 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, diabetes and allergic to ibuprofen. The patient received unspecified concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6198) via an unspecified route of administration in left arm on 25Feb2021 at 12.15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021 at 1600, the patient experienced injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat and dry sinuses. No treatment was received for the adverse events. The clinical outcome of injection site pain, 101.3-degree fever, chills, joint pain, headache, tiredness, feeling unwell, chest pain, dry throat, dry sinuses was resolved on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Dizziness, Nausea
Clinical narrative: Immediately felt light headed, soon after felt dizzy; Bad nausea; Stomach felt uneasy; This is a spontaneous report received from a contactable other healthcare professional, the patient. A non-pregnant female patient of unspecified age received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via an unspecified route of administration in the right arm on 09Mar2021 at 14:00 as single dose for COVID-19 immunisation. Medical history was not reported. The patient had no allergies to medications, food and other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medication included flu vaccine (MANUFACTURER UNKNOWN) on 24Feb2021. The patient did not receive any other vaccines within 2 weeks prior to the COVID-19 vaccine. On 09Mar2021 at 14:00, the patient experienced light headed, nausea and stomach discomfort. The patient did not receive any treatment for the reported events. The clinical outcome of events light headed, nausea and stomach discomfort were recovered on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Pain, Pyrexia
Clinical narrative: Chills; Low grade fever; Fatigue; Body aches; This is a spontaneous report received from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: GN6208), via unspecified route of administration in the left arm on 10Mar2021 at 13:30 (at the age of 32-years-old) as single dose for COVID-19 immunisation. Medical history included COVID-19 infection as it was reported that prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID-19 vaccine. The patient was not allergic to medications, food, or other products. Concomitant medication included birth control medication (unspecified), which the patient received within 2 weeks of vaccination. On 11Mar2021 at 10:00, the patient experienced chills, low grade fever, fatigue and body aches. The patient did not receive any treatment for these events. The clinical outcome of the events chills, low grade fever, fatigue and body aches were recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Chills; Low grade fever; Fatigue; Body aches; This is a spontaneous report received from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: GN6208), via unspecified route of administration in the left arm on 10Mar2021 at 13:30 (at the age of 32-years-old) as single dose for COVID-19 immunisation. Medical history included COVID-19 infection as it was reported that prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID-19 vaccine. The patient was not allergic to medications, food, or other products. Concomitant medication included birth control medication (unspecified), which the patient received within 2 weeks of vaccination. On 11Mar2021 at 10:00, the patient experienced chills, low grade fever, fatigue and body aches. The patient did not receive any treatment for these events. The clinical outcome of the events chills, low grade fever, fatigue and body aches were recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Inappropriate schedule of product administration, Lymphadenopathy, Vaccination site pain
Clinical narrative: Dose 1- 03Feb2021 and Dose 2- 19Mar2021; Sore arm at injection site; Swollen lymph node left armpit; sore underarm; This is a spontaneous report  from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via unspecified route of administration in the left arm on 19Mar2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic back pain (chronic lower back pain) and latex allergy. Concomitant medications included oxycodone and acetaminophen (MANUFACTURER UNKNOWN) and etonogestrel; ethinyl estradiol (NUVARING) from unknown date for unspecified indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via unspecified route of administration in the left arm on 03Feb2021 at 16:00 (at the age of 40-years-old)  as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 20Mar2021 at 21:00, patient experienced sore left arm at injection site, swollen lymph node at left armpit, and and sore underarm .The patient received first dose on 03Feb2021 and second dose on 19Mar2021 (Inappropriate schedule of vaccine administration). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome for sore left arm at injection site, swollen lymph node at left armpit, and and sore underarm and inappropriate schedule of vaccine administration was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Myalgia, Pyrexia
Clinical narrative: Low-grade Fever, 99.8 - 100.8; moderate headaches; moderate exhaustion; moderate muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202); via an unspecified route of administration in the left arm on 03Mar2021 (at the age 69-year-old) at 08:30 as a single dose for COVID-19 immunisation. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3249); via an unspecified route of administration in the left arm on 11Feb2021 at 15:30 as a single dose for COVID-19 immunisation. Medical history included asthma, atrial fibrillation (A-fib), fibromyalgia, high blood pressure, cerebellar ataxia. The patient had known allergy to propantheline, codeine, eggs and milk. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included ELIQUIS, guaifenesin (MANUFACTURER UNKNOWN), carbidopa-levodopa (MANUFACTURER UNKNOWN), furosemide (MANUFACTURER UNKNOWN); all from an unknown date administered for unknown indications. On 04Mar2021, the patient experienced low-grade fever 99.8- 100.8 (unspecified units) for 24 hours, moderate headaches for 48 hours, moderate exhaustion for 72 hours and moderate muscle aches for 48 hours. On an unknown date, the patient underwent body temperature recording and the result was 99.8-100.8 (Unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of low-grade fever resolved on 05Mar2021 and clinical outcome of the events moderate headache and muscle ache were resolved on 06Mar2021 whereas, event moderate exhaustion was resolved on 08Mar2021. Since the vaccination, the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Pain in extremity, Pyrexia
Clinical narrative: fatigue; temperature of 102F; headache; sore arm; This is a spontaneous report received from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ENG198) via an unspecified route of administration in the left arm on 11Mar2021 at 11:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer. The patient was allergic to erythromycin. The patient was diagnosed with COVID-19 prior to vaccination. The patient had not tested positive for COVID-19 since the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included beclomethasone (QVAR), montelukast (MANUFACTURER UNKNOWN), olmesartan medoxomil (MANUFACTURER UNKNOWN), anastrozole (MANUFACTURER UNKNOWN) all for unknown indications and from an unknown date and unknown if ongoing. On 11Mar2021 at 15:00, the patient experienced fatigue, temperature of 102F, headache and sore arm. Fever lasted 24 hours and started 8 hours after shot. Fatigue started a few hours after shot and was severe for 24 hours (could not get out of bed) and gradually went away over a week. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of events fatigue, temperature of 102F, headache and sore arm was recovered on an unknown date in Mar2021. No follow up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chest discomfort, Chills, Fatigue
Clinical narrative: General body pain / full body ache; Muscle pain / full body musclepains; Fever (100 degree); Nausea; Vomiting / Multiple vomoting; Joint pain; Chills; Tiredness; Feeling unwell; Swollen lymph nodes / Swelling of lymph nodes; Tight chest / Slight tight chest and heartbeat; This is a spontaneous report received from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on the left arm, on 18Mar2021 at 16:00 hours for COVID-19 immunisation. Medical history included myasthenia gravis. Concomitant medications included cellcept (MANUFACTURER UNKNOWN), mestinon (MANUFACTURER UNKNOWN), and 10mg steroids (MANUFACTURER UNKNOWN); all for an unspecified indication and unknown drug start date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 18Mar2021 at 18:00 hours, patient experienced events general body pain (full body aches), muscle pain (full body muscle pains), fever (100 degree), nausea, vomiting (multiple), joint pain, chills, tiredness, feeling unwell, swollen lymph nodes (swelling of lymph nodes), tight chest (slight tight chest and heart beat). No therapeutic measures were taken. The clinical outcome for events general body pain, muscle pain, fever, nausea, vomiting, joint pain, chills, tiredness, feeling unwell, swollen lymph nodes, tight chest were resolving at the time of reporting. The patient had not tested positive for COVID-19 since having the vaccine.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Malaise, Myalgia, Nausea, Pain
Clinical narrative: General body pain / full body ache; Muscle pain / full body musclepains; Fever (100 degree); Nausea; Vomiting / Multiple vomoting; Joint pain; Chills; Tiredness; Feeling unwell; Swollen lymph nodes / Swelling of lymph nodes; Tight chest / Slight tight chest and heartbeat; This is a spontaneous report received from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on the left arm, on 18Mar2021 at 16:00 hours for COVID-19 immunisation. Medical history included myasthenia gravis. Concomitant medications included cellcept (MANUFACTURER UNKNOWN), mestinon (MANUFACTURER UNKNOWN), and 10mg steroids (MANUFACTURER UNKNOWN); all for an unspecified indication and unknown drug start date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 18Mar2021 at 18:00 hours, patient experienced events general body pain (full body aches), muscle pain (full body muscle pains), fever (100 degree), nausea, vomiting (multiple), joint pain, chills, tiredness, feeling unwell, swollen lymph nodes (swelling of lymph nodes), tight chest (slight tight chest and heart beat). No therapeutic measures were taken. The clinical outcome for events general body pain, muscle pain, fever, nausea, vomiting, joint pain, chills, tiredness, feeling unwell, swollen lymph nodes, tight chest were resolving at the time of reporting. The patient had not tested positive for COVID-19 since having the vaccine.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: General body pain / full body ache; Muscle pain / full body musclepains; Fever (100 degree); Nausea; Vomiting / Multiple vomoting; Joint pain; Chills; Tiredness; Feeling unwell; Swollen lymph nodes / Swelling of lymph nodes; Tight chest / Slight tight chest and heartbeat; This is a spontaneous report received from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on the left arm, on 18Mar2021 at 16:00 hours for COVID-19 immunisation. Medical history included myasthenia gravis. Concomitant medications included cellcept (MANUFACTURER UNKNOWN), mestinon (MANUFACTURER UNKNOWN), and 10mg steroids (MANUFACTURER UNKNOWN); all for an unspecified indication and unknown drug start date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 18Mar2021 at 18:00 hours, patient experienced events general body pain (full body aches), muscle pain (full body muscle pains), fever (100 degree), nausea, vomiting (multiple), joint pain, chills, tiredness, feeling unwell, swollen lymph nodes (swelling of lymph nodes), tight chest (slight tight chest and heart beat). No therapeutic measures were taken. The clinical outcome for events general body pain, muscle pain, fever, nausea, vomiting, joint pain, chills, tiredness, feeling unwell, swollen lymph nodes, tight chest were resolving at the time of reporting. The patient had not tested positive for COVID-19 since having the vaccine.  No follow-up attempts are needed. No further information is expected.